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 Idiopathic pulmonary fi brosis (IPF) is a deadly dis-ease that carries a poor prognosis for which thera-
peutic options are limited. 1-5 As the understanding of 
the disease has grown, similar but distinct entities 
have been differentiated from IPF, 6 but the disease 
remains heterogeneous in many respects, with ongo-
ing uncertainty of the diagnosis in many cases. 7 In 
2000, a committee of experts in the fi eld, under the 
auspices of the American Thoracic Society (ATS) and 
the European Respiratory Society (ERS), published a 
consensus statement for the diagnosis and treatment 
 The American Thoracic Society and European Respiratory Society guidelines for the diagnosis 
and treatment of idiopathic pulmonary fi brosis (IPF) have been published recently. However, the 
infl uence, practical application, and utility of the prior consensus statement for IPF have never 
been evaluated. Demographics, diagnostic criteria, pulmonary function data, and disposition of 
patients with IPF evaluated at an interstitial lung disease center between 2000 and 2009 were 
analyzed. Enrollment in clinical drug trials, lung transplantation, and mortality also were assessed. 
A total of 521 patients with IPF were evaluated, with pulmonary function testing available in 446. 
In the 64% of patients without surgical lung biopsy, the most common major criterion not fulfi lled 
was bronchoscopy. Lung transplantation was performed in 16.1% of patients, whereas 27.4% of 
prescreened patients were enrolled in a prospective drug study. Patients with mild, moderate, 
and severe disease categorized by FVC % predicted had median survivals of 55.6, 38.7, and 
27.4 months, respectively. The attrition rate of patients who survived beyond 5 years was attenu-
ated in subsequent years. IPF remains a deadly disease with a poor prognosis. Bronchoscopy does 
not appear to be required for an accurate diagnosis. A minority of patients were accommodated 
within a clinical trial or with transplantation. Categorization by baseline FVC % predicted effec-
tively discriminates groups with different long-term outcomes. Our analysis supports the view 
that the value of statements also can be realized in the subsequent demonstration of their impact 
on patient management, which might enable further refi nements in a continuous, iterative redis-
covery process.  CHEST 2011; 140(1):221–229 
 Abbreviations:  ATS  5 American Thoracic Society; D lco  5 diffusing capacity of lung for carbon monoxide; ERS  5 European 
Respiratory Society; HRCT  5 high-resolution CT; IPF  5 idiopathic pulmonary fi brosis; PFT  5 pulmonary function test 
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of IPF. 8 The goal of this statement was to homogenize 
the diagnosis and management of the disease and to 
provide a foundation for the characterization of the 
disease. This statement has been updated in a 
recently published guideline. 9  However, to our knowl-
edge, the impact of the 2000 statement has never 
been evaluated in a busy clinical practice. Given the 
publication of the guideline, it is incumbent on the 
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5% cut point) into approximate terciles based on their FVC % 
predicted. A similar analysis based on approximate terciles was 
performed for diffusing capacity of lung for carbon monoxide 
(D lco ) % predicted. A survival analysis incorporating both the 
FVC and the D lco % predicted also was performed. In this 
regard, within the three FVC groups, serial decile cut points in 
D lco % predicted were tested, and the best discriminator of sur-
vival based on the smallest  P value was chosen for report. Patient 
mortality was ascertained through the hospital’s advanced lung 
disease program database and the Social Security Death Index. 
The study was approved by the Inova Fairfax Institutional Review 
Board (IRB #10.059). 
 Statistics 
 All demographic and pulmonary function data are pre-
sented as means with ranges if continuous or as frequencies if 
categorical. Kaplan-Meier survival curves were calculated using 
GraphPad, version 5.0 software (GraphPad Software, Inc; La Jolla, 
California). Differences in the 3-year survival are reported where 
median survival was not achieved in the duration of follow-up. 
Differences in survival curves were evaluated using the log-rank 
test. Cox proportional hazards modeling was used to account 
for the infl uence of the following factors on mortality: age, sex, 
FVC % predicted, and D lco % predicted. Hazard modeling 
was performed using SAS, version 9.2 software (SAS Institute; 
Cary, North Carolina). 
 Results 
 Baseline Data and Demographics 
 There were 521 patients with IPF who were seen 
and evaluated in the clinic during the 10-year period. 
The demographics of the cohort and PFT data at the 
time of initial evaluation, which were available in 
446 of the patients, are shown in  Table 1 . The date of 
the PFT was in many cases different from the date of 
the patient’s initial evaluation. Most of the PFTs 
(273 of 446, 61.2%) were within 90 days of the ini-
tial evaluation, with a median time difference of 
45.7 days. In most cases (337 of 446, 75.6%), the 
PFTs were obtained prior to patients’ initial evalua-
tion, whereas in 93 of 446 (20.8%), they were obtained 
after the patient was evaluated, and in 16 of 446 
(3.6%), they were obtained on the same day. A his-
togram distribution of the initial FVC % predicted is 
shown in  Figure 1 . 
 How Closely Was the ATS/ERS Statement Followed? 
 In the 2000 statement, there were three major cri-
teria required for a diagnosis of IPF to be made if 
the patient had undergone a sur gical lung biopsy to 
confi rm the diagnosis: the exclusion of other known 
causes of interstitial lung disease, abnormal pulmo-
nary function studies, and bibasilar reticular abnor-
malities with minimal ground glass opacities on HRCT 
scan. 8 The same three major criteria plus a broncho-
scopic evaluation that suggested no alternative diag-
nosis on transbronchial biopsy specimen or BAL were 
required if there had been no surgical biopsy. 
community to evaluate the usefulness of the previous 
statement to determine whether there are lessons to 
be learned that might be applicable to the way in 
which the new guideline should be viewed and 
interpreted. 
 The long-term prognosis of patients with IPF has 
been derived mostly from studies performed prior 
to the publication of the 2000 statement. 2-4,10,11 More 
recent information about prognosis has emanated from 
large, multicenter clinical trials, but these have only 
provided relatively short follow-up periods of 2 years 
or less. 12-16 In addition, these studies often only included 
highly selected patients because many were excluded 
by virtue of their age, disease severity, or comorbid 
conditi ons. Therefore, we sought to characterize the 
nature and outcomes of all patients with IPF who 
were seen and evaluated at a tertiary-care interstitial 
lung disease program over the 10-year period since 
the publication of the ATS/ERS statement in 2000. 
 Specifi cally, there were three major aims of this 
study. First, we sought to determine how readily the 
ATS/ERS statement could be applied in a busy inter-
stitial lung disease clinic (ie, how “user friendly” it was) 
and to assess whether any variation in the application 
of the statement had an impact on the accuracy of the 
diagnostic process. Second, we sought to assess how 
commonly patients were recruited into cli nical trials 
of novel therapies and how many received lung trans-
plantations as recommended by the statement. Third, 
we sought to determine long-term IPF outcomes 
in a well-categorized, all-inclusive patient cohort in 
which the suggestions of the 2000 statement were 
followed prospectively. 
 Materials and Methods 
 We performed a review of all patients with IPF who were seen 
at the Inova Fairfax Hospital Interstitial Lung Disease Clinic 
between January 2000 and November 2009. The clinic maintains 
a database of all patients evaluated, with data entered prospec-
tively at the time of their initial evaluation. This database was used 
as the source in identifying the cohort. When available, chart 
reviews were performed for missing data to provide as complete a 
data set as possible. Patients were given a diagnosis of IPF based 
on their clinical presentation, high-resolution CT (HRCT) scan 
appearance, and, where there was any element of doubt, surgical 
lung biopsy. Patient demographics and pulmonary function test 
(PFT) data at or near the time of presentation were collated and 
analyzed. The prediction equations of Knudson et al 17  were used 
in patients whose PFTs were obtained at the Inova Fairfax pulmo-
nary laboratory. If the patients presented with PFTs performed at 
another laboratory, these data were entered based on that labora-
tory’s prediction equation standard. Records of the number of 
patients considered for entry into clinical trials of therapy and for 
lung transplantation evaluation were interrogated. 
 A number of survival analyses were performed, including a sur-
vival analysis of all patients with IPF, a similar analysis with trans-
plantation recipients excluded, an analysis by early and late eras, 
and an analysis based on severity of PFT indices at presentation. 
For the latter analysis, patients were divided (at the closest 
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 In the majority of cases, HRCT scanning was con-
sistent with IPF. In the absence of an HRCT scan 
study consistent with IPF, surgical lung biopsy was 
performed in 187 of 521 (35.9%) of the cases ( Fig 2 ). 
Bronchoscopy with transbronchial biopsy or BAL 
was not performed in any of the patients after eval-
uation. Of the 334 patients who were given a diag-
nosis without a surgical lung biopsy or bronchoscopy, 
49 subsequently underwent lung transplantation. 
The explanted specimens showed changes consistent 
with usual interstitial pneumonia in 45 cases and 
indiscernible end-stage fi brosis in three. The one 
remaining patient, a 42-year-old white man, had 
advanced fibrosis with evidence of noncaseating 
granulomas. 
 The 2000 ATS/ERS statement required the pres-
ence of three of four minor criteria to be present in 
addition to the four major features if no surgical 
biopsy had been performed. These minor criteria 
included age  . 50 years, insidious onset of other-
wise unexplained dyspnea on exertion, duration of 
illness  . 3 months, and bibasilar inspiratory crack-
les (dry or “Velcro type” in quality). 
 In our series, there were 40 patients who were 
aged  , 50 years, of whom 22 had a confi rmatory 
surgical lung biopsy procedure . Lung transplanta-
tion was performed in 12 of these patients (six of 
whom did not have a prior surgical lung biopsy), 
with histologic confi rmation of the diagnosis in all 
12 explant specimens. Thus, 28 of the 40 patients 
aged  , 50 years had biopsy-proven IPF. Most patients 
presented with insidious onset of unexplained exer-
tional dyspnea, but 16.8% had no dyspnea on presen-
tation. Of these, approximately 12% of patients 
presented with cough alone, whereas 5% of the patients 
were asymptomatic at the time of diagnosis. Ninety-
nine percent of the symptomatic patients had their 
symptoms for  . 3 months. The presence of inspira-
tory crackles was noted in 96.8% of the patients. Of 
the patients who did not have a surgical lung biopsy, 
94.3% did not fulfi ll all the major criteria (primarily 
due to the lack of a bronchoscopy), whereas only 
2.9% failed to fulfi ll three of the four minor diag-
nostic criteria as recommended. 8 
 Role of Lung Transplantation and Clinical 
Trials of Therapy 
 Patients were evaluated and deemed appropriate 
candidates for lung transplantation on the basis of 
the standard accepted eligibility criteria. 18 There were 
93 of 521 (17.9%) patients who were deemed appro-
priate and listed for lung transplantation, 84 (16.1%) 
of whom subsequently survived to have the proce-
dure ( Fig 2 ). Of these patients, 35 (41.6%) had under-
gone a prior surgical lung biopsy. Therefore, there 
 In our series, all patients had other known causes of 
interstitial lung disease excluded through a thorough 
history, physical examination, and connective tissue 
disease serologies. Baseline pulmonary function data 
were consistent with IPF in the majority of instances. 
There were only 61 of 446 (13.7%) patients with a 
“normal” FVC (defined as  . 80% predicted). Of 
the 394 patients with both FVC and D lco data 
available, only 10 (2.5%) had a D lco   80% pre-
dicted, and five (1.3%) had both a normal FVC % 
predicted and D lco % predicted. In these subgroups, 
18 of 61 (29.5%), 4 of 10 (40%), and 2 of 5 (40%) had 
surgical biopsy specimens that confi rmed the diag-
nosis of IPF. Of the 61 patients with normal FVC % 
predicted, there was follow-up spirometry performed 
in 32 patients at a mean of 20.1 months. In this 
subgroup, the FVC decreased from a mean of 90.2% 
to 84.5%, with 13 of 32 (40.6%) below the 80% 
threshold of normality on follow-up. 
 Table 1— Demographics of the IPF Cohort 
Demographic Value
Age, y 65 (30-90 )
Sex, %
 Male 71.7
 Female 28.3
Ethnicity, %
 White 77.7
 Black 13.8
 Hispanic 4.6
 Asian 2.7
 Native American 1.2
FVC, % predicted 61.01 (16-108)
FEV 1 , % predicted 66.40 (15-133)
D lco , % predicted 40.96 (9-102)
Data are presented as mean (range) unless otherwise indicated. 
D lco  5 diffusing capacity of lung for carbon monoxide; IPF  5 idiopathic 
pulmonary fi brosis.
 Figure 1. Histogram distribution of the initial FVC % predicted 
at the time of presentation. 
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Our primary survival analysis excluded patients who 
underwent lung transplantation and included only 
those in whom PFTs were available. This group (n  5 357) 
demonstrated a median survival of 45.87 months 
from the time of their initial PFTs ( Fig 4 ). Exami-
nation of the survival curve demonstrates a biphasic 
curve with an initial attrition rate characterized by a 
constant linear slope over the fi rst 48 to 60 months. 
Thereafter, the curve appears fl atter, attesting to a 
better subsequent outcome for those patients with 
IPF who survived the fi rst 5 years. Survival by era also 
was evaluated with patients divided into two periods: 
2000-2004 (n  5 247) and 2005-2009 (n  5 274). No 
difference was demonstrated. The median survival 
of the 43 study patients enrolled in a clinical trial 
was 52.13 months compared with the 34.33 months for 
the nonstudy patients ( P  5 .03). Cox proportional haz-
ards modeling revealed age, male sex, FVC % pre-
dicted, and D lco % predicted to all be signifi cant 
predictors of mortality, with hazard ratios of 1.02, 
1.88, 0.98, and 0.90, respectively. 
 Inclusion of the 84 IPF transplantation recipients 
resulted in a median survival for all patients with PFT 
data (n  5 441) of 47.8 months, with the transplanta-
tion cohort having a median survival of 63.3 months 
from their initial PFT data set. Survival of all lung 
transplantation recipients from the time of transplan-
tation was 83.1% at 1 year, 60.6% at 3 years, and 41% 
at 5 years, with a median survival of 55.5 months for 
this group. 
 Lastly, we stratifi ed the nontransplantation patients 
with available pulmonary function data and long-term 
follow-up (n  5 359) into approximate terciles as fol-
lows: mild (FVC   70% predicted) (n  5 110), moder-
ate (FVC 55% to 69% predicted) (n  5 129), and severe 
(FVC  , 55% predicted) (n  5 120) disease. The median 
survival of the three groups was 55.6 months, 
38.7 months, and 27.4 months, respectively ( P  5 .008) 
( Fig 5 ). A similar analysis based on approximate 
D lco terciles also was performed in those with 
available data (n  5 317). The D lco % predicted also 
appeared to discern groups with distinct survival 
differences; specifi cally, those with a D lco   50% 
predicted (n  5 101) had a median survival of 
67.3 months compared to those with a D lco of 35% 
to 49% (n  5 112) and a D lco  , 35% (n  5 104), whose 
median survivals were 47.8 months and 31.3 months, 
respectively ( P  5 .0003) ( Fig 6 ). We also assessed 
various cut points of the D lco % predicted to see 
whether this allowed further discrimination of sur-
vival in the three FVC severity groups ( Fig 7 ). For 
the mild patients, a D lco  , 60% appeared to dis-
cern the subgroup with a worse outcome (3-year 
survival of 61% vs 80%;  P  5 .002), whereas in those 
with moderate disease, a D lco   40% identifi ed 
the subgroup with worse outcomes; specifi cally, these 
 Figure 2. Flowchart of disposition of patients with IPF in rela-
tion to surgical lung biopsy, enrollment in clinical trials, and lung 
transplantation. *  5 fi ve study patients listed for and received 
lung transplants; D Lco  5 diffusing capacity of lung for carbon 
monoxide; IPF  5 idiopathic pulmonary fi brosis; PFT  5 pulmonary 
function test. 
was histopathologic evidence of IPF in 45.1% 
(235 of 521) of the cases (48 explantation samples 
plus 187 surgical biopsy samples) ( Fig 2 ). All but one 
of the 84 patients receiving transplantations at our 
institution received a single lung transplantation. 
 In November 2002, we instituted a log for all 
patients considered for enrollment in a clinical trial. 
During the period from November 2002 to November 
2009, 418 patients were evaluated, of whom 243 were 
deemed unsuitable for prescreening because of read-
ily apparent reasons. The remaining 175 were pre-
screened 259 times for potential enrollment in one of 
seven phase 2 or 3 prospective trials of a therapeutic 
agent for IPF. Included among the 259 screening 
episodes were 58 patients who were rescreened for 
the same study. Therefore, 26 patients were pre-
screened for two different studies. Signed consent 
for enrollment was obtained in 81 patients, 33 of 
whom were subsequently disqualifi ed from random-
ization and were regarded as study “screen failures.” 
Of the patients who were prescreened, therefore, 
48 (27.4%) qualifi ed and were randomized into a 
prospective clinical drug study, representing only 
11.5% of all the patients with IPF evaluated during 
this time period. In addition, two of these patients were 
enrolled in a subsequent study after completion of 
the initial trial. The exclusionary factors and the stage 
that patients were eliminated from further consider-
ation for study enrollment are shown in  Figure 3 . Of 
the 48 study patients, fi ve subsequently went on to 
receive lung transplantations. 
 IPF Outcomes 
 For the whole cohort (N  5 521), the median sur-
vival from the time of evaluation was 41.2 months. 
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 Figure 4. Survival of patients with IPF from the time of initial 
PFT, with transplantation recipients excluded. See Figure 2 leg-
end for expansion of abbreviations. 
 Figure 3. Flowchart demonstrating exclusionary factors and the stage that patients were eliminated from study enrollment into clinical 
trials of novel therapies. *  5 two patients enrolled twice in sequential studies; **  5 usually too much honeycombing; Bx  5 biopsy; 
HRCT  5 high-resolution CT; PH  5 pulmonary hypertension; ?diagnosis  5 sponsor uncertainty regarding diagnosis. See Figure 2 legend 
for expansion of other abbreviations. 
patients had a median survival of 27.8 months com-
pared with 59.9 months for those with a D lco  . 40% 
( P  5 .0005). For the severe group, the small sub-
group of patients (n  5 15) with a D lco   20% 
predicted had a median survival of 11.47 months 
compared with the remaining patients (n  5 77) in 
the severe category whose median survival was 
35.2 months ( P  5 .026). 
 Discussion 
 IPF is a disease with a poor prognosis that appears 
unchanged over the past decade in comparison with 
the pre-ATS/ERS statement period. The median sur-
vival in our nontransplantation IPF cohort of about 
3.5 years is very similar to survival rates reported 
prior to the publication of the statement. 2-4 Of patients 
who were considered for enrollment in a prospective 
therapeutic study, only 27% qualified despite the 
availability and contiguity of multiple clinical trials, 
whereas only 16% of the patients qualifi ed for and 
received a lung transplantation. We demonstrate that 
an appropriate and accurate diagnosis of IPF can be 
attained without bronchoscopy. Stratifi cation of patients 
into mild, moderate, or severe disease on the basis of 
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of IPF in the absence of surgical lung biopsy. This 
procedure is undertaken primarily to rule out other 
conditions but is performed inconsistently among dif-
ferent centers and regions of the world. If a surgical 
lung biopsy is not deemed necessary, the diagnostic 
approach adopted at our institution has been to 
forego the performance of bronchoscopy in the context 
of the appropriate clinical setting and characteristic 
HRCT scan. Indeed, it appears that this approach does 
not compromise the accuracy of diagnosis. Specifi -
cally, the survival of the nontransplantation patients 
whose condition was confi rmed by surgical lung biopsy 
specimens was similar to those who did not undergo 
lung biopsy (data not shown), which supports the 
notion that the two groups had the same disease. In 
addition, there were 45 cases in whom there was no 
diagnostic biopsy and who subsequently underwent 
lung transplantation. In all but one of these cases, the 
explanted lung either demonstrated usual interstitial 
pneumonia-like changes or end-stage fi brosis with no 
other pathologic pattern suggestive of an alternate 
diagnosis. 
 Another of the ATS/ERS major criteria is the pres-
ence of abnormal lung function that includes evi-
dence of restriction and impaired gas exchange. 8 It is 
noteworthy that, in our cohort with evaluable PFT 
data, 14% did not have restrictive physiology, whereas 
2.5% had a normal diffusing capacity. In a future era 
that will hopefully include therapies that slow the rate 
of decline in lung function, the earlier diagnosis of 
IPF appears crucial. Therefore, we are of the opinion 
that consideration of the diagnosis should not be 
precluded by the absence of discernable physiologic 
abnormalities because the opportunity to have an 
impact on disease progression at the earliest stage 
might be lost. The clinical features that constitute the 
minor criteria were fulfi lled in the majority of patients; 
thus, only a small proportion of patients without a 
surgical lung biopsy failed to meet three of the four 
criteria recommended in the ATS/ERS statement. 
 The most defi nitive management recommendation 
from the statement is to refer appropriate patients for 
a transplantation evaluation and to enroll patients 
with IPF in clinical trials of therapy. 8 The propor-
tion of all patients with IPF who can be thus accom-
modated has never been previously quantifi ed to 
our knowledge. Despite the availability of sequen-
tial studies of novel therapy, in our series, only 
46% (81 of 175) consented for enrollment, of whom 
almost 40% “screen failed.” Qualifi cation for enroll-
ment in a clinical trial appeared to be associated with 
improved outcomes, perhaps refl ecting the bias of 
the inclusionary criteria, which mostly sought to iden-
tify patients with early disease, and the exclusionary 
criteria, which similarly sought to exclude patients 
with significant comorbidities. The small subset of 
their initial FVC % predicted allowed discrimination 
of groups with distinctly different long-term survivals. 
The D lco appeared to allow further delineation of 
survival from among these patients. 
 IPF is a condition that is heterogeneous in many 
respects, including its presentation, unpredictable 
clinical course, histopathologic features, and progno-
sis. These characteristics have resulted in heterogene-
ity among physicians in making an accurate diagnosis 
and in the management of these patients. The goals of 
the 2000 ATS/ERS statement were to enable a uni-
form approach to the diagnosis of IPF and manage-
ment of patients with this condition as well as to 
identify defi ciencies in the knowledge base and thereby 
provide a foundation and impetus for future research. 8 
Although the guideline has been published recently, to 
our knowledge, there has been no systematic review of 
how it was implemented or the lessons learned from 
the diagnostic and management recommendations 
of the consensus statement. We sought to evaluate 
and provide insight into specifi c aspects of the state-
ment in a broad group of patients with IPF. This 
included an evaluation of the need for bronchoscopy 
in the absence of a surgical lung biopsy, insight into 
the opportunity for transplantation and enrollment 
in clinical trials, and an assessment of the long-term 
natural history of IPF as diagnosed under the umbrella 
of the 10-year-old statement. 
 Bronchoscopy is one of the four major criteria sug-
gested by the ATS/ERS statement for the diagnosis 
 Figure 6. IPF survival stratifi ed by the initial D lco % predicted. 
See Figure 2 legend for expansion of abbreviations. 
 Figure 5. IPF survival stratifi ed by the initial FVC % predicted. 
See Figure 2 legend for expansion of abbreviation. 
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benign disease course. 19-21 Indeed, it has been com-
monly assumed that the attenuated survival demon-
strated in these older studies was because of the 
inclusion of patients with diseases other than IPF. 
Ours is, therefore, the first description of an appar-
ent survivor group in the most recent era of patients 
with nonspecifi c interstitial pneumonia excluded. 
 There are limitations to our study mostly based on 
the retrospective nature of its design. Missing data in 
a few patients resulted from many causes, among 
them was our inability to perform PFTs on all patients 
owing to insurance and other constraints encoun-
tered in a busy clinical practice, a situation shared by 
most practicing pulmonologists in the United States 
and elsewhere. Our analysis of bronchoscopy only 
included patients with IPF and did not assess the util-
ity of this procedure in ruling out other conditions. 
For those patients with clinical features consistent 
with other conditions, bronchoscopy might still be 
the procedure of choice. We also do not provide an 
assessment of the treatment aspects of the statement 
because it has been our practice not to offer the state-
ment’s suggestion of combined therapy with corticos-
teroids and either azathioprine or cyclophosphamide. 8 
Additionally, when assessing survival, we did not 
account for any other therapies implemented. How-
ever, it is well recognized that as yet, no commonly 
available effective medical therapies can alter or 
modify the course and outcomes of IPF. The survival 
of our lung transplantation cohort was very similar to 
that reported by the International Society for Heart 
and Lung Transplantation, 22 but we did not perform 
a specific survival benefit analysis from among the 
patient population because this too has been previously 
patients who qualifi ed and were enrolled in a clinical 
trial also raises a cautionary note about the applica-
tion of data from such studies to the general IPF 
population. It is interesting to note that only about 
one-third of the patients could be accommodated 
with either enrollment in a clinical trial and/or lung 
transplantation, underscoring the large, unmet need 
and current treatment void for most patients with IPF. 
 We demonstrate in our large cohort of patients with 
IPF followed prospectively over the course of 10 years 
that survival has not changed substantively. Our delin-
eation and demonstration of a difference in outcomes 
among the various groups based on their initial base-
line FVC % predicted provides a rational and simple 
structure to the concept of mild, moderate, and severe 
disease. We chose to categorize patient severity on 
the basis of the FVC % predicted because this is the 
more commonly performed pulmonary function param-
eter. However, the D lco % predicted did perform 
slightly better in discerning survival as indicated by 
the hazard ratios generated from our Cox propor-
tional hazards modeling. In any event, the D lco % 
predicted did appear to have added utility in further 
discriminating survival from among the three FVC 
groups. 
 Another interesting observation is the survival of 
patients (approximately one-quarter) after the fi rst 4 to 
5 years from the time of diagnosis, which appears 
different from the outcomes of de novo patients. 
Interestingly, this “survivor” group appears to be 
equally distributed among disease severity groups. A 
survival “tail” has been described previously in older 
publications prior to the recognition of nonspecifi c 
interstitial pneumonia as a distinct entity with a more 
 Figure 7. IPF survival stratifi ed by the initial FVC % predicted (mild [  70%], moderate [55%-69%], and severe [ , 55%] disease) and 
D lco % predicted. See Figure 2 legend for expansion of abbreviations. 
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performed and validated. 23-26 We could not ascertain 
the exact cause of death in all patients to know that 
these were all truly respiratory in nature. However, 
we believe that all-cause mortality is the best end 
point because we did account for all patients with 
IPF, including those who might have had signifi cant 
contributory comorbidities. 27 
 In conclusion, we have characterized the course 
and outcomes in a broad group of patients with IPF 
in the era since the publication of the ATS/ERS state-
ment 10 years ago. In doing so, we have demonstrated 
that the mortality from IPF remains unchanged and 
unacceptably high. Our data also support the mod-
ifi cation of the original ATS/ERS statement for the 
diagnosis of IPF. Further, we have shown that only 
a minority of patients with IPF can be accommo-
dated within clinical therapeutic studies or with 
lung transplantation. Approximately one-quarter 
of patients with IPF appear to run an abrogated 
course with signifi cantly better long-term outcomes. 
We also have provided a framework and justifi cation 
for the characterization of disease severity based 
on the baseline FVC % predicted. Finally, we have 
demonstrated that the value of statements and guide-
lines also lies in the lessons learned from their imple-
mentation. We suggest that such future documents 
should provide an inherent framework for the sub-
sequent assessment of their efficacy and impact 
on patient care. 
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